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There is insufficient evidence that the surgical treatment of asymptomatic infrarenal aneurysms >5.5 cm. is beneficial to
patients. This is the result of serious complications of aneurysm surgery and the dearth of information from randomized
trials. Based on evidence from the literature we defined scenarios and translated data into natural frequency trees to im-
prove understanding of the uncertainty of help versus harm due to treatment of aneurysms.
Our analysis shows that the majority of patients can expect little on longevity from surgery while they are at risk of
dying from surgery or suffering from serious morbidity.
We conclude that, as long as uncertainty persist, patients should be treated in hospitals that can show very low surgical
mortality and major morbidity rates. To further resolve the problem of uncertainty randomized trials for larger aneurysms
should be performed. Important issues to discuss are the lower and upper limits of the diameter of the aneurysms and the
age and risk profiles of the patients to be included in such trials.
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asymptomatic infrarenal aortic aneurysms with a di-
ameter 5.5 cm prevents untimely death from rup-
ture. Many surgeons and patients therefore consider
surgery to be significantly beneficial. This belief is
based mainly on information from several case series,
published over the last 50 years. However, British and
American randomized small aneurysm trials have
shown that, on comparison with watchful waiting,
early open surgery does not improve the 5-year sur-
vival rate if the aneurysm diameter does not exceed
5.5 cm.1e3 Recently the EVAR trial 2 showed that
endovascular treatment of high risk patient with an
aneurysm diameter 5.5 cm did not improve survival
over no intervention.4 Randomized trials for surgery
of larger aneurysms in patients with a lower perioper-
ative risk are absent.
Innumeracy, i.e. the inability to think in numbers,
obscures clear thinking and communication. The
aim of this article is to elucidate quantitative balanc-
ing while taking into account the uncertainty about
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aneurysms. A number of recently developed concepts
can be helpful in specifying the assumed benefits of
treatment.5e7 Scenario analyses and presenting natu-
ral frequencies for the respective outcomes may help
to show ourselves and patients what can happen,
and how likely these outcomes are.8
Theoretical Considerations
The main outcome of aneurysm treatment is dichoto-
mous: life or death. Surgery aims to reduce premature
death from aneurysm rupture. Useful terms in defin-
ing the effects of surgery and comparing them with
conservative treatment are absolute risk reduction
(ARR) and number needed to treat (NNT). The ARR
is defined as the difference in death rate between com-
parable surgical and non-surgical patients at a particu-
lar time horizon e.g. after 5 years. The NNT is defined
as the number of patients that need to be treated over
a specific period of time to prevent one death from
rupture. It is calculated from the inverse of the abso-
lute risk reduction: 1/ARR. If we assume a 10%
reduction in death rate after 5 years for surgically
treated patients compared with non-surgical patients,rved.
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patients need to be treated in order to prevent death
from rupture in one of them within 5 years. The
ARR here is the combined result of both deaths
from rupture prevented by surgery and deaths due
to perioperative complications.
The disadvantage of surgery is that harm may be
done. Terms expressing the magnitude of harm are
absolute risk increase (ARI) and number needed to
harm (NNH). The ARI can be defined as the propor-
tion of patients with surgical complications. The
NNH is the number of patients who receive treatment
for one additional patient being harmed by treatment.
The NNH is defined as the reciprocal of the absolute
risk increase: 1/ARI.
We know a patient can suffer death, stroke or myo-
cardial infarction, immediately or shortly after aneu-
rysm surgery. If a 5% mortality rate is associated
with asymptomatic abdominal aneurysm surgery,
this translates into an NNH of 20 (1/0.05). If survival
is accompanied by a 5% risk of stroke or myocardial
infarction we must consider another 5% risk increase
in the remaining 95 patients. This translates into an
aggregate absolute risk increase of 0.05þ 0.95
0.05¼ 0.0975% which in turn translates into a total
NNH of 1/0.0975z 10. It is clear that when morbidity
is included in the definition of harm, NNH is substan-
tially reduced.
The NNT and NNH provide an opportunity for an
alternative look at the data. If we operate on 1000
patients, we will improve survival by preventing
death from rupture in 150, induce mortality in 50
and in approximately 48 patients who survive the
operation (0.95 0.05 1000) we will induce serious
harm as a result of complications.
For simplicity’s sake we have excluded the effects
of minor perioperative complications, delayed mortal-
ity and major morbidity resulting from ruptured false
aneurysms, graft infection and occlusion, or other as-
pects of harm. A small additional increase in absolute
risk as a result of delayed major complications will
further affect the benefit/harm balance of the opera-
tion. It should be noted that in perioperative mortality
life ends within 30 days, whereas fatal rupture can
occur at any point in the future, leading to a smaller
associated loss in life years.
Estimation of Outcome Combinations Within
Different Scenarios
One of the advantages of the small aneurysm trials
is that they can help us to build scenarios for the
surgical treatment of larger aneurysms and provideguidance in creating a balance between benefit and
harm.1e3 Perioperative mortality was 5.8% in the
British- and 2.4% in the American small aneurysm trials.
Overall survival at 6 years was about 65e75% in both
the surgical and the surveillance groups. The cause of
death in the large majority of patients was concomi-
tant cardiovascular disease. In general doctors and
patients overestimate the beneficial effect of interven-
tions for asymptomatic disease. Therefore we assume
that, in combination with efficacy data from other
clinical trials including asymptomatic patients with
cardiovascular disease, surgical treatment is unlikely
to have a major effect on survival in larger aneurysms
and that the effect at best would be modest.9e11 An
overview reported an average 30-day mortality after
open surgery of 8.2% in population-based series and
3.8% in hospital-based series,12 while for endovascu-
lar treatment mortality rate is 1e2%.13,14 This can be
translated into a reasonable estimate of the ARI.
In most studies complications in surviving patients
are excluded as a primary endpoint. We believe that
events such as serious stroke, permanent dialysis, dis-
abling myocardial infarction or pulmonary insuffi-
ciency, paraplegia, or leg amputation should be
included especially in view of the modest effects of
surgery on longevity.
We provide an example of the quantitative balanc-
ing of benefit and harm, using the hypothetical results
of a randomized trial in 1000 patients with infrarenal
aneurysms with a diameter of 5.5 to 6.5 cm. This trial
compares surgical treatment with watchful waiting
until the aneurysm exceeds 6.5 cm. Although it is un-
certain whether such a trial would show any benefit
from surgery in terms of 5-year survival, we postulate
three scenarios: an increase in survival of 5%, 10%,
and 20%. Perioperative mortality is varied from 2%
to 5% to 10%. The results are shown in Table 1. The
data in this table show that the majority of patients
can expect little from surgery in any of the scenarios,
and that the benefits are extremely small if the in-
crease in survival is only 5% to 10% with a 5% perio-
perative mortality rate. With a 5% perioperative
mortality rate and a 5% gain in 5-year survival, pre-
mature death from rupture is prevented in 100 pa-
tients out of a 1000, but this comes at the cost of 50
perioperative deaths (scenario B).
In Figs. 1 and 2 we elaborate on some scenarios
from Table 1. We have added a 10% complication
rate in patients surviving the operation and have
drawn frequency trees to better understand what
really happens to patients. Only serious and unac-
ceptable complications are introduced, and ‘minor’
complications like wound infection, deep venous
thrombosis etc. are excluded.Eur J Vasc Endovasc Surg Vol 32, December 2006
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The data above show how delicate the balance is. All
patients are at risk of dying from surgery or suffering
serious complications, whereas death from rupture
will only be prevented in a minority. As there are no
data from randomized larger aneurysm trials there
is a considerable chance that surgery for aneurysms
with a diameter of 5.5e6.5 cm will not benefit asymp-
tomatic patients. In aneurysms >6.5 cm we do not
elaborate on the hypothetical scenarios, as there are
too many uncertain variables, making all assumptions
insecure. We feel that it would go too much against
the grain to cast doubt on the benefits of surgery for
aneurysms >6.5 cm, though it should be noted that
these benefits have not yet been demonstrated due
to a dearth of information from randomized trials.
Table 1. Number of patients in whom death from rupture is
prevented or induced by surgery
Perioperative mortality rate
2% 5% 10%
5% Gain in 5-year survival
Deaths from
rupture prevented
70 100 150
Deaths from surgery 20 50 100
Scenario A B C
10% Gain in 5-year survival
Deaths from
rupture prevented
120 150 200
Deaths from surgery 20 50 100
Scenario D E F
20% Gain in 5-year survival
Deaths from
rupture prevented
220 250 300
Deaths from surgery 20 50 100
Scenario G H I
Includes three different scenarios of increase in survival at 5 years
after surgery at 5, 10, and 20%. Figures are calculated for a cohort
of 1000 patients with different perioperative mortality rates.Eur J Vasc Endovasc Surg Vol 32, December 2006In our examples we did not address differences
between low and high risk patients, the complexity
of the aneurysm, or patients’ values. It is difficult to
imagine that surgery in asymptomatic high risk pa-
tients can be beneficial. Complex suprarenal and thor-
acoabdominal aneurysms carry even higher mortality
and morbidity rates. This view is supported by the
results of the EVAR trial 2, which showed that endo-
vascular treatment of asymptomatic infrarenal aneu-
rysms in high risk patients had a 9% perioperative
mortality rate and did not improve survival.4
Our calculations demonstrate the need for some
form of shared decision-making. So far patients’
values have been insufficiently studied. We lack
empirical information about the way patients regard
postoperative complications when informed of the
minimal effects of surgery and the fact that measures
taken to prevent death from aneurysm rupture will
prolong life only in a few.
Where Hence?
As long as clinicians continue to recommend surgery
for asymptomatic aneurysms, patients should only be
operated on in hospitals that can show very low sur-
gical mortality and major morbidity rates. This will go
some way in reducing patients’ uncertainty regarding
the balance between benefit and harm. The question is
what mortality and morbidity rates are acceptable and
whether these can be achieved. It is hard to answer.
Our scenarios show that these percentages should
preferably be in the range of 1% to 3% for mortality
and <5% for major morbidity. Endovascular treat-
ment of aneurysms in patients with a low or interme-
diate perioperative risk may help achieve these
numbers, although long-term results of this type of
treatment must be awaited.13e16 Yet, to resolve the1000
patients
100
increased survival 
900
no increase in survival
50
died from surgery
850
survived surgery
90
no complications 
10
major complications
85
major complications
765
no complications
Fig. 1. Frequency tree of scenario B. Cohort of 1000 patients. Increase in survival at 5 years after surgery 5%, perioperative
death rate 5%, major complication rate in patients who survive surgery 10%.
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patients
150
increased survival 
850
no increase in survival
50
died from surgery
800
survived surgery
135
no complications 
15
major complications
80
major complications
720
no complications 
Fig. 2. Frequency tree of scenario E. Cohort of 1000 patients. Increase in survival at 5 years after surgery 10%, perioperative
death rate 5%, major complication rate in patients who survive surgery 10%.problem of uncertainty regarding help or harm the
best step would be to perform a randomized trial
for larger aneurysms with well-defined endpoints.
In this era of evidence-based medicine such a study
is of vital importance. Key issues to discuss are the
lower and upper limit of the diameter of the aneu-
rysms and the age and risk profiles of the patients
to be included in such trials. Additionally we should
study the way patients regard and trade off benefits
of surgery against complications.
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